Parametrica Management Ltd purchased a new position in Alkermes Plc (NASDAQ:ALKS) during the first quarter, Holdings Channel reports. The institutional investor purchased 8,854 shares of the company’s stock, valued at approximately $518,000.
Other institutional investors have also recently bought and sold shares of the company. Sei Investments Co. increased its stake in shares of Alkermes Plc by 1,223.7% in the third quarter. Sei Investments Co. now owns 88,225 shares of the company’s stock worth $4,150,000 after buying an additional 81,560 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Alkermes Plc by 11.8% in the third quarter. Daiwa Securities Group Inc. now owns 3,800 shares of the company’s stock worth $179,000 after buying an additional 400 shares during the last quarter. M&T Bank Corp increased its stake in shares of Alkermes Plc by 31.9% in the third quarter. M&T Bank Corp now owns 6,625 shares of the company’s stock worth $312,000 after buying an additional 1,604 shares during the last quarter. KBC Group NV increased its stake in shares of Alkermes Plc by 45.9% in the third quarter. KBC Group NV now owns 14,168 shares of the company’s stock worth $667,000 after buying an additional 4,457 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its stake in shares of Alkermes Plc by 1.8% in the third quarter. Neuberger Berman Group LLC now owns 9,282 shares of the company’s stock worth $437,000 after buying an additional 163 shares during the last quarter. 95.52% of the stock is currently owned by institutional investors and hedge funds.
Shares of Alkermes Plc (NASDAQ:ALKS) traded up 0.37% during midday trading on Thursday, reaching $57.16. The company’s stock had a trading volume of 829,611 shares. The stock’s 50-day moving average price is $57.85 and its 200-day moving average price is $54.98. The company’s market cap is $8.72 billion. Alkermes Plc has a 12-month low of $36.71 and a 12-month high of $62.50.
Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 15th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.11. The firm had revenue of $213.50 million for the quarter, compared to the consensus estimate of $206.38 million. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The company’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.14) EPS. On average, analysts expect that Alkermes Plc will post $0.04 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Parametrica Management Ltd Purchases New Stake in Alkermes Plc (ALKS)” was first posted by sleekmoney and is the property of of sleekmoney. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at http://sleekmoney.com/parametrica-management-ltd-purchases-new-stake-in-alkermes-plc-alks/1739534.html.
A number of brokerages recently weighed in on ALKS. Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 price objective on shares of Alkermes Plc in a research report on Monday, April 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $51.00 price objective on shares of Alkermes Plc in a research report on Thursday, March 16th. TheStreet raised Alkermes Plc from a “d+” rating to a “c” rating in a research report on Wednesday, February 15th. Finally, Cowen and Company reaffirmed a “positive” rating and set a $65.00 price objective on shares of Alkermes Plc in a research report on Tuesday, March 21st. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $63.55.
In related news, CMO Elliot Ehrich sold 11,983 shares of the business’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $54.32, for a total value of $650,916.56. Following the sale, the chief marketing officer now owns 62,640 shares in the company, valued at approximately $3,402,604.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP James M. Frates sold 25,000 shares of the business’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $59.08, for a total value of $1,477,000.00. Following the completion of the sale, the senior vice president now owns 144,053 shares in the company, valued at approximately $8,510,651.24. The disclosure for this sale can be found here. Insiders sold a total of 112,783 shares of company stock worth $6,553,698 in the last quarter. Company insiders own 4.75% of the company’s stock.
Alkermes Plc Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/parametrica-management-ltd-purchases-new-stake-in-alkermes-plc-alks/1739534.html
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.